TIRZEPATIDE 60MG | Fat Loss Dual Agonist

Tirzepatide 60mg is a research-grade GIP/GLP-1 receptor agonist studied for maximal dual-incretin weight loss, insulin sensitivity and hepatic lipid metabolism. This 3 ml vial containing 60 mg presentation is intended for laboratory investigation of high-mass supply for extended dual-agonist studies. Tirzepatide combines GIP and GLP-1 receptor agonism in a single fatty-acylated peptide. The dual action amplifies glucose-dependent insulin secretion and appetite suppression while potentially improving adipose-tissue lipid storage and reducing ectopic fat.

The 60 mg vial provides enough material for chronic studies and analytical characterisation. SURMOUNT-1 (Jastreboff et al., New England Journal of Medicine, 2022) established that tirzepatide produces substantial, dose-dependent weight loss in adults with obesity. SURPASS-2 (Frias et al., New England Journal of Medicine, 2021) showed superior glycaemic control versus semaglutide. Researchers use the 60 mg presentation for long-duration studies, multiple cohorts and receptor-signalling assays requiring larger peptide quantities.

It also supports comparisons with triple agonists and combination therapies. Prepare single-use aliquots after reconstitution to avoid freeze-thaw degradation. Given the high mass, verify concentration by UV or mass spectrometry and use titration schedules that mimic clinical ramp-up. The vial should remain frozen and protected from light until reconstitution. Use bacteriostatic water or the buffer recommended for the assay, add the diluent slowly against the vial wall, and let the powder dissolve without vigorous agitation.

Aliquot immediately to avoid repeated freeze-thaw. Key questions concern the durability of weight loss, the long-term effect on lean mass and bone, and whether dual agonism reduces the gastrointestinal burden compared with triple agonism. Sold for laboratory research only. Not for human or veterinary use, and not for diagnostic or therapeutic applications.